World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
68
Citations
15591
World Ranking
2600
National Ranking
1241

W. Martin Kast publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where W. Martin Kast sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 237 publications — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

W. Martin Kast D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where W. Martin Kast sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 68 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

W. Martin Kast is affiliated with the University of Southern California in the United States and has a research focus primarily in the field of Medicine, with a significant emphasis on Oncology, Immunology, and Epidemiology. Their work spans several specialized subfields including Molecular Biology and Surgery.

The main topics covered in Kast's research include:

  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • Cervical Cancer and HPV Research
  • Hepatitis B Virus Studies
  • Immune Cell Function and Interaction
  • Virus-based Gene Therapy Research
  • Vaccine Coverage and Hesitancy

Kast has contributed to numerous scientific publications, with recent papers including:

  • Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials (2022, Cancer Treatment Reviews)
  • TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy (2020, Frontiers in Immunology)
  • Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929) (2020, Clinical Cancer Research)
  • Understanding medical mistrust and HPV vaccine hesitancy among multiethnic parents in Los Angeles (2022, Journal of Behavioral Medicine)
  • Examining multilevel influences on parental HPV vaccine hesitancy among multiethnic communities in Los Angeles: a qualitative analysis (2023, BMC Public Health)

Their frequent co-authors include Diane M. Da Silva, Ruben Prins, Daniel J. Fernandez, Joseph D. Bonner, and Rebeca Sanz-Pamplona. These collaborations indicate a network of researchers working closely on related topics in cancer and immunology research.

W. Martin Kast has published extensively in venues such as:

  • Cancer Research
  • Frontiers in Immunology
  • Regular and Young Investigator Award Abstracts
  • Cancers
  • Viruses

The breadth of Kast's research spans fundamental studies in immune cell function and gene therapy to applied clinical investigations, particularly focused on cervical cancer and immunotherapeutic approaches.

Best Publications

  • Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells.

    Sanne Weijzen;Paola Rizzo;Mike Braid;Radhika Vaishnav

  • Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells

    Dmitry I. Gabrilovich;Markwin P. Velders;Eduardo M. Sotomayor;W. Martin Kast

  • Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro

    Ton N.M. Schumacher;Marie-Thérèse Heemels;Jacques J. Neefjes;W.Martin Kast

  • Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model

    Heather L. Greenstone;John D. Nieland;Karin E. de Visser;Marloes L. H. De Bruijn

  • T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer

    Maria Mercader;Barbara K. Bodner;Micheal T. Moser;Pamela S. Kwon

  • Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes.

    W.Martin Kast;Rienk Offringa;Peter J. Peters;Arie C. Voordouw

  • Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

    Ulrich Keilholz;Jeffrey Weber;James H. Finke;Dmitry I. Gabrilovich

  • Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.

    Raymond M. Wong;Ron R. Scotland;Roy L. Lau;Changyu Wang

  • Mechanisms used by human papillomaviruses to escape the host immune response

    Shreya Kanodia;Laura M. Fahey;W. Martin Kast

  • Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C.

    David J. Adelstein;John A. Ridge;Maura L. Gillison;Anil K. Chaturvedi

  • Peptide selection by MHC class I molecules.

    Ton N. M. Schumacher;Marloes L. H. De Bruijn;Leen N. Vernie;W. Martin Kast

  • Defined Flanking Spacers and Enhanced Proteolysis Is Essential for Eradication of Established Tumors by an Epitope String DNA Vaccine

    Markwin P. Velders;Sanne Weijzen;Gretchen L. Eiben;Amira G. Elmishad

  • Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes

    Michel P.M. Vierboom;Hans W. Nijman;Rienk Offringa;Ellen I.H. van der Voort

  • Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)

    Sylvia Janetzki;Katherine S. Panageas;Leah Ben-Porat;Jean Boyer

  • The Evolving Field of Human Papillomavirus Receptor Research: A Review of Binding and Entry

    Adam B. Raff;Andrew W. Woodham;Laura M. Raff;Joseph G. Skeate

  • Human Dendritic Cells Are Activated by Chimeric Human Papillomavirus Type-16 Virus-Like Particles and Induce Epitope-Specific Human T Cell Responses In Vitro

    Michael P. Rudolf;Steven C. Fausch;Diane M. Da Silva;W. Martin Kast

  • HEAD AND NECK SQUAMOUS CELL CANCER AND THE HUMAN PAPILLOMAVIRUS: SUMMARY OF A NATIONAL CANCER INSTITUTE STATE OF THE SCIENCE MEETING,

    David J. Adelstein;John A. Ridge;Maura L. Gillison;Anil K. Chaturvedi

  • Human Papillomavirus Virus-Like Particles Do Not Activate Langerhans Cells: A Possible Immune Escape Mechanism Used by Human Papillomaviruses

    Steven C. Fausch;Diane M. Da Silva;Michael P. Rudolf;W. Martin Kast

  • Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16‐induced tumors

    Mariet C. W. Feltkamp;Gienke R. Vreugdenhil;Michel P. M. Vierboom;Elisabeth Ras

  • The S100A10 Subunit of the Annexin A2 Heterotetramer Facilitates L2-Mediated Human Papillomavirus Infection

    Andrew W. Woodham;Diane M. Da Silva;Joseph G. Skeate;Adam B. Raff

Frequent Co-Authors

Cornelis J. M. Melief
Cornelis J. M. Melief ISA Pharmaceuticals (Netherlands)
Maurizio Chiriva-Internati
Maurizio Chiriva-Internati The University of Texas MD Anderson Cancer Center
Martin J. Cannon
Martin J. Cannon University of Arkansas for Medical Sciences
Andrew N. Gray
Andrew N. Gray US Forest Service
John T. Schiller
John T. Schiller National Institutes of Health
Rienk Offringa
Rienk Offringa German Cancer Research Center
Jan W. Drijfhout
Jan W. Drijfhout Leiden University Medical Center
René E. M. Toes
René E. M. Toes Leiden University Medical Center
Michael I. Nishimura
Michael I. Nishimura Loyola University Chicago
Sjoerd H. van der Burg
Sjoerd H. van der Burg Leiden University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related healthcare degrees can open diverse career pathways. Many students explore nursing programs to build foundational expertise in patient care and biological sciences. Those without a nursing background may find online programs designed specifically for non-nurses appealing. For example, there are excellent options like online rn programs for non nurses in florida that offer flexible learning with a focus on practical skills.

If time and entry requirements are a concern, accelerated programs provide a faster route into the nursing field. Some of the easiest accelerated nursing programs to get into allow students to quickly earn a Bachelor of Science in Nursing (BSN), building a strong foundation useful in advanced immunology careers.

For those interested in shorter, more accessible credentials, exploring the which lpn programs are easiest to get into can be a practical step. Licensed Practical Nurse (LPN) programs integrate well with immunology-related roles focused on patient support and care delivery.

Advancing into specialized roles such as Family Nurse Practitioner (FNP) can enhance clinical expertise and career prospects. Identifying the easiest fnp program expands opportunities for those aiming to work closely with patients in immunology-related healthcare settings.

Best Scientists Citing W. Martin Kast

Trending Scientists

Recently Published Articles